45 CFR § 180 compliance
C · 70
This hospital published part of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
○Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
11,589
Insurances with rates
9
CPT / HCPCS codes
10,511
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $89,890 | $154,661 | $192,797 | 6 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $89,890 | $173 | $192,797 | 24 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $48,859 | $84,064 | $104,792 | 6 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $48,859 | $55.35 | $104,792 | 24 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $47,016 | $80,893 | $100,840 | 6 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $47,016 | $131 | $100,840 | 24 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $43,675 | $75,145 | $93,674 | 6 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $43,675 | $127 | $93,674 | 24 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $33,990 | $58,481 | $72,901 | 6 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $33,990 | $146 | $72,901 | 24 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $28,265 | $48,632 | $60,623 | 6 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $28,265 | $238 | $60,623 | 24 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $27,625 | $47,531 | $59,251 | 6 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $27,625 | $85.6 | $59,251 | 24 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $26,958 | $46,383 | $57,820 | 6 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $26,958 | $27.48 | $57,820 | 24 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $62,016 | $26,312 | $45,271 | $56,434 | 6 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $62,016 | $26,312 | $35.1 | $56,434 | 24 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $24,532 | $42,209 | $52,616 | 6 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $24,532 | $103 | $52,616 | 24 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $24,370 | $41,931 | $52,270 | 6 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $24,370 | $50.74 | $52,270 | 24 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $23,586 | $40,581 | $50,587 | 6 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $23,586 | $9,806 | $50,587 | 15 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $22,183 | $38,168 | $47,579 | 6 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $22,183 | $87.58 | $47,579 | 24 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $21,250 | $36,562 | $45,577 | 6 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $21,250 | $20.26 | $45,577 | 24 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $47,856 | $20,304 | $34,935 | $43,549 | 6 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $47,856 | $20,304 | $8,442 | $43,549 | 15 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $47,856 | $20,304 | $34,935 | $43,549 | 6 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $47,856 | $20,304 | $8,442 | $43,549 | 15 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $47,856 | $20,304 | $34,935 | $43,549 | 6 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $47,856 | $20,304 | $8,442 | $43,549 | 15 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $47,856 | $20,304 | $34,935 | $43,549 | 6 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $47,856 | $20,304 | $8,442 | $43,549 | 15 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $47,856 | $20,304 | $34,935 | $43,549 | 6 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $47,856 | $20,304 | $8,442 | $43,549 | 15 |
| 0803T | TCAT RMV&RPL2CHMB LDLS PM RV | $47,856 | $20,304 | $34,935 | $43,549 | 6 |
| 0803T | TCAT RMV&RPL2CHMB LDLS PM RV | $47,856 | $20,304 | $8,442 | $43,549 | 15 |
| J9223 | LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION | $47,756 | $20,262 | $34,862 | $43,458 | 6 |
| J9223 | LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION | $47,756 | $20,262 | $196 | $43,458 | 24 |
| J9301 | OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION | $47,423 | $20,121 | $34,619 | $43,155 | 6 |
| J9301 | OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION | $47,423 | $20,121 | $72.02 | $43,155 | 24 |
| 27786 | HC CL TX LAT MALLE WO MNP | $47,307 | $20,071 | $34,534 | $43,049 | 6 |
| 27786 | HC CL TX LAT MALLE WO MNP | $47,307 | $20,071 | $230 | $43,049 | 22 |
| C9765 | REVASC INTRA LITHOTRIP-STENT | $45,091 | $19,131 | $32,916 | $41,033 | 6 |
| C9765 | REVASC INTRA LITHOTRIP-STENT | $45,091 | $19,131 | $7,954 | $41,033 | 22 |
| C9766 | REVASC INTRA LITHOTRIP-ATHER | $45,091 | $19,131 | $32,916 | $41,033 | 6 |
| C9766 | REVASC INTRA LITHOTRIP-ATHER | $45,091 | $19,131 | $7,954 | $41,033 | 22 |
Showing top 50 of 11,589 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.